3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
15
Terminated
3
Active not recruiting
3
Withdrawn
2
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
3
NET
2
Endocrine
2
CNS
1
Conditions
Neuroendocrine Tumors
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoid Tumor
1
Adenoma, Islet Cell
1
Interventions
lutetium Lu 177 dotatate
16
Magnetic Resonance Spectroscopy
14
gallium Ga 68 dotatate
9
Specimen Handling
8
Everolimus
8
pembrolizumab
7
cabozantinib
6
Cisplatin
6
fluorodopa F 18
5
Etoposide
5
trametinib
4
surufatinib
4
lanreotide
4
dabrafenib
4
cemiplimab
4
X-Rays
4
Temozolomide
4
Nivolumab
4
Lutetium-177
4
Lutetium
4
Fluorodeoxyglucose F18
4
Carboplatin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
olaparib
3
lenvatinib
3
copper dotatate CU-64
3
Transurethral Resection of Prostate
3
Thyrotropin Alfa
3
Surveys and Questionnaires
3
Somatostatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Octreotide
×
Endocrine
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled
NCT05701241
2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4
Recruiting
270 enrolled